CVS Health provides preferred access to Amgen's Repatha for high cholesterol

US pharmacy health care provider CVS Health will provide preferred access to Amgen’s (Nasdaq: AMGN) Repatha (evolocumab), it has been announced.

Repatha, approved by the Food and Drug Administration on August 27 this year, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C); and as an adjunct to diet and other LDL-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), who require additional lowering of LDL-C.

Anthony Hooper, executive vice president of global commercial operations at US biotech major Amgen, said: “Ensuring access to Repatha for appropriate patients is among Amgen’s highest priorities and we are delighted that CVS Health has granted the drug a preferred position on their commercial formularies. This is an important milestone for patients and we will continue to engage constructively with other payers to enable patients to have access to Repatha.”